Journal of Clinical & Experimental Pharmacology

Abstract

A Systemic Review on Aducanumab and Lecanamab in the Development of ARIA in Alzheimer's Disease

Ankit Verma*, Roshi and Priyanshi Sharma

Alzheimer's is a condition of neurodegenerative disease, which caused cognitive and memory loss in the patient. The condition usually progresses in those over 65, and it causes dementia to develop along with memory loss and impairments in cognitive behavior. By 2050, there will be 113 million cases of dementia worldwide, up from the 50 million cases there were in 2010. Amyloid plaques and neurofibrillary tangles are the major cause of AD. Formation of Aβ associated with the conversion of APP protein into Aβ through γ-secretase enzyme and formation of neurotangillary fibre are associated with hyperphosphorylation of tau protein. Disease modifying therapy like aducanumab, bapineuzumab, gantenerumab, donanemab, crenezumab, solanezumab and lecanamab are developed. It is believed that these Anti Aβ antibodies are very significantly reduce the level of Aβ. Aducanumab and lecanamab showing good therapeutic effect with lesser degree of side effect. ARIA-A and ARIA-H are most commonly associated side effect of these anti Aβ antibody. In this review we are focused on the comparison between Aducanumab and lecanamab, their mechanism of reducing Aβ level, binding profile with soluble and insoluble plaque and their side effect.

Published Date: 2023-10-25; Received Date: 2023-09-25